Apocynum propolis soft capsule and preparation method thereof

Abstract

The invention relates to the field of medicines and health care, in particular to an apocynum propolis soft capsule and a preparation method thereof. The apocynum propolis soft capsule is mainly composed of content and capsule skin. The content is mainly prepared from, by weight, 40-76 parts of apocynum extract, 50-85 parts of propolis powder, 230-300 parts of grape seed oil and 8-10 parts of beeswax; the capsule skin is mainly prepared from, by weight, 100-150 parts of gelatin, 40-60 parts of glycerin, 0.15-0.25 part of brown iron oxide, 0.045-0.075 part of allura red and an appropriate amount of purified water. According to the apocynum venetum propolis soft capsule and the preparation method thereof, compatibility of medicines is simple and reasonable, by combining the three raw materials of the apocynum venetum extract, the propolis powder and the grape seed oil, the high density lipoprotein liver cholesterol (HDL-C) in human bodies is increased, the low density lipoprotein cholesterol (LDL-C) is decreased, the metabolism of triglyceride (TG) in the human bodies is regulated, cholesterol content is lowered, and the capsule comprehensively and effectively prevents the occurrenceof cardiovascular and cerebrovascular diseases.

Description

Technical field [0001] The invention relates to the field of medicine and health care, in particular to a soft capsule of apocynum propolis and a preparation method thereof. Background technique [0002] In the past 30 years, the blood lipid level of the Chinese population has gradually increased, and the prevalence of dyslipidemia has increased significantly. The overall prevalence of dyslipidemia in Chinese adults is as high as 40.4%. The increase in serum cholesterol levels in the population will lead to an increase of about 9.2 million cardiovascular events in my country from 2010 to 2030. National survey results in recent years have shown that the prevalence of hypercholesterolemia is 4.9%; the prevalence of hypertriglyceridemia (TG) is 13.1%; the prevalence of low-high-density lipoprotein cholesterol (HDL-C) is The disease rate was 33.9%. That is, dyslipidemia characterized by elevated low-density lipoprotein cholesterol (LDL-C) or TC is an important risk factor for athe...

AI Technical Summary

Problems solved by technology

At present, statin lipid-lowering drugs and cholesterol absorption inhibitors (ezetimibe, etc.) are often used clinically to reduce LDL-C levels. However, cholesterol absorption inhibitors combined with statins may cause side effects such as increased transaminases and myalgia.